2002 |
Թϴͷ Medical Research Inc. is established as a clinical research subsidiary in New Jersey, the United States.
|
2004 |
Թϴͷ adopts the “Company with Committees” system.
Թϴͷ Europe Ltd. is established as a European regional headquarters (holding company) in London, the United Kingdom.
Թϴͷ Pharmaceuticals India Pvt. Ltd. is established as a pharmaceutical sales subsidiary in Mumbai, India.
|
2005 |
Թϴͷ S.r.l is established as a pharmaceutical sales subsidiary in Milan, Italy.
Թϴͷ Pharma AG is established as a pharmaceutical sales subsidiary in Zurich, Switzerland.
The Corporate Mission is added to the Թϴͷ Articles of Incorporation.
Թϴͷ AB is established as a pharmaceutical sales subsidiary in Stockholm, Sweden.
Honorary chairman and Թϴͷ's second president Yuji Naito passes away at age 85.
|
2006 |
Թϴͷ Australia Pty. Ltd. is established as a pharmaceutical sales subsidiary in Sydney, Australia.
Թϴͷ rolls out its fifth mid-term plan, the “Dramatic Leap Plan.”
Թϴͷ (Singapore) Pte. Ltd. and Թϴͷ Clinical Research Singapore Pte. Ltd. are established as a pharmaceutical sales subsidiary and clinical research subsidiary, respectively, in Singapore.
Թϴͷ acquires four anticancer agents from Ligand Pharmaceuticals Inc. in the United States.
EF-Թϴͷ Farmacêutica, Unipessoal Lda. is established as a pharmaceutical sales subsidiary in Lisbon, Portugal.
|
2007 |
Թϴͷ Manufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom.
Թϴͷ acquires Morphotek Inc., a bioventure specialized in antibody research, in the United States.
Թϴͷ Pharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India.
Թϴͷ SA/NV is established as a pharmaceutical sales subsidiary in Brussels, Belgium.
|
2008 |
Թϴͷ acquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States.
Թϴͷ Machinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery.
Rheumatoid arthritis treatment Humira is launched in Japan.
|
2009 |
Թϴͷ GesmbH is established as a pharmaceutical sales subsidiary in Vienna, Austria.
The European Knowledge Centre opens as a European strategic base in Hertfordshire, the United Kingdom.
European Knowledge Centre
The Թϴͷ Product Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D.
Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations.
The Թϴͷ Knowledge Centre, India opens as a manufacturing and process research base in Vizag, India.
Թϴͷ Knowledge Centre, India |
2010 |
The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award.
Koishikawa Knowledge Center
Թϴͷ Limited is established as a pharmaceutical sales subsidiary in Ontario, Canada.
Production headquarters transforms to a global “Թϴͷ Demand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing.
Թϴͷ (Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China.
Anticancer agent Halaven is launched in the United States.
Թϴͷ signs a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge.
H3 Biomedicine Inc. is established as a research subsidiary in the United States.
|
2011 |
The Great East Japan Earthquake strikes.
Թϴͷ rolls out its sixth mid-term plan, “HAYABUSA.”
Թϴͷ Participações Ltda. is established as a pharmaceutical sales subsidiary in São Paulo, Brazil.
Halaven is launched in Europe and Japan.
Թϴͷ Laboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico.
|
2012 |
Թϴͷ signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020.
Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ).
Antiepileptic agent Fycompa is launched in Europe.
|
2013 |
Limited Liability Company Թϴͷ is established as a pharmaceutical sales subsidiary in Moscow, Russia.
Թϴͷ co-establishes the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public–private partnership to advance development of new health technologies for the developing world.
Թϴͷ initiates free of charge provision of diethylcarbamine tablets produced at its Vizag plant in India to WHO for use in the treatment of lymphatic filariasis.
|
2014 |
Fycompa is launched in the United States.
Թϴͷ China Holdings Ltd. is established as a holding company in Suzhou, China.
|
2015 |
Anticancer agent Lenvima is launched in the United States, Japan and Europe.
Թϴͷ completes acquisition of Chinese generic pharmaceutical company Liaoning Tianyi Biological Pharmaceutical Co., Ltd. (new trading name: Թϴͷ (Liaoning) Pharmaceutical Co., Ltd.)
|
2016 |
Թϴͷ rolls out its seventh mid-term plan “EWAY2025.”
EA Pharma Co., Ltd. is established as a gastrointestinal specialty pharmaceutical company.
Fycompa is launched in Japan.
|
2017 |
Թϴͷ joins global partnership to address non-communicable diseases.
Թϴͷ pledges continued support for lymphatic filariasis elimination.
Թϴͷ commits funding to the 2nd phase of Global Health Innovative Technology Fund activities.
Collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments including aducanumab expanded.
|
2018 |
Թϴͷ agrees upon a strategic collaboration for Lenvima with Merck & Co., Inc., Kenilworth, N.J., U.S.A.
New Suzhou plant in China commences full-scale operation.
Lenvima (hepatocellular carcinoma) is launched in China.
|
2019 |
Թϴͷ Center for Genetics Guided Dementia Discovery (G2D2) in Massachusetts, U.S., commences full-scale operation.
G2D2
Parkinson’s disease treatment Equfina is launched in Japan.
Fycompa and Halaven are launched in China.
|
2020 |
The WHO Declares COVID-19 a Pandemic.
“NouKNOW” (pronounced “NOH-NOH”), a new tool for self-assessment of brain performance (brain health) is launched in Japan.
DAYVIGO (insomnia treatment) is launched in the United States and Japan.
Թϴͷ Vietnam Co., Ltd. is established as a pharmaceutical sales subsidiary in Ho Chi Minh City, Vietnam.
Unlimit Health Limited is established in Shanghai, China.
|
2021 |
Թϴͷ rolls out its eighth medium-term business plan "EWAY Future &Beyond".
Alzheimer’s disease treatment ADUHELM is granted accelerated approval and launched in the United States.
Թϴͷ enters into a global strategic collaboration agreement with Bristol-Myers Squibb Company for MORAb-202.
The Tokyo Olympics take place.
Թϴͷ Israel Ltd. is established as a pharmaceutical sales subsidiary in Tel Aviv, Israel.
Թϴͷ celebrates its 80th anniversary.
|
2022 |
Թϴͷ and Biogen amend collaboration agreements on ADUHELM.
Թϴͷ makes Arteryex Inc., a company that plans and develops software, its subsidiary.
Թϴͷ Pharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa.
Թϴͷ signs the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases.
Deep Human Biology Learning (DHBL), a new R&D organization, commences full-scale operation.
|
2023 |
Alzheimer’s disease treatment LEQEMBI is granted accelerated approval and launched in the United States.
Թϴͷ commits funding to the 3rd phase of Global Health Innovative Technology Fund.
LEQEMBI is granted traditional approval by the FDA.
Theoria technologies Co., Ltd. is established as a digital business company in Tokyo, Japan.
LEQEMBI is launched in Japan.
|